Talk about getting ahead of yourself.
Last June, Celator Pharmaceuticals proudly displayed a large poster touting its experimental Vyxeos medication as an effective salve for treating acute myeloid leukemia. The poster was, in fact, one of countless placards featured prominently on the exhibit floor at the American Society of Clinical Oncology meeting in Chicago, a sort of Woodstock for cancer doctors and eager investors.
